Dr. Shane Johnson, GM of BayMedica, InMed’s subsidiary, is a guest on The Water Tower Hour podcast. Host Jesse Redmond, Senior Analyst at Water Tower Research interviewed Shane live at the Benzinga Cannabis Capital Conference in Chicago September 28th.
In this interview, Shane talks about InMed and BayMedica’s rare cannabinoid expertise and the synergies between the two companies, the market opportunities for rare cannabinoids, the importance of cannabinoid consistency for consumer products and the challenges of the current cannabinoid landscape.
Shane Johnson enters the podcast at 25:50.
Highlights from Shane’s interview with Jesse:
- 25:50 – Why attend Benzinga Cannabis Capital Conference? Who’s in attendance?
- 27:10 – What do InMed and BayMedica specialize in? What are rare cannabinoids?
- 28:00 – What is THCV? What is THCV used for?
- 28:50 – What is considered a rare cannabinoid? What other cannabinoids, other than THC and CBD are found in higher quantities in the plant? Does BayMedica commercialize plant-based cannabinoids?
- 31:15 – How are BayMedica’s and InMed’s businesses differentiated? Do InMed and BayMedica both focus on rare cannabinoids? How do the two businesses complement each other?
- 33:30 – What are the market opportunities for rare cannabinoids in pharmaceutical and health and wellness. How are they different? What are the challenges for the cannabinoid business?
- 35:20 – What is driving the recent revenue growth at InMed/BayMedica?
- 37:20 – What does defined spectrum mean? Why are consumer interested in defined spectrum for their cannabinoid-based products? Why is cannabinoid consistency such an important quality in consumer products?
- 40:00 – What are the biggest challenges facing the cannabinoid industry?
- 44:20 – What is the 2024 outlook for BayMedica?
Podcast available on multiple platforms